166 related articles for article (PubMed ID: 2438482)
1. Effect of angiotensin converting enzyme inhibitors on the vasoconstrictor action of angiotensin I on isolated rat kidney.
Schmidt M; Giesen-Crouse EM; Krieger JP; Welsch C; Imbs JL
J Cardiovasc Pharmacol; 1986; 8 Suppl 10():S100-5. PubMed ID: 2438482
[TBL] [Abstract][Full Text] [Related]
2. [Effects of conversion enzyme inhibitors on the synthesis of angiotensin II by the isolated rat kidney].
Krieger JP; Welsch C; Giesen-Crouse E; Schmidt M; Imbs JL
Arch Mal Coeur Vaiss; 1987 Jun; 80(6):862-5. PubMed ID: 2959231
[TBL] [Abstract][Full Text] [Related]
3. Effects of angiotensin I and angiotensin II in blood vessels: greater influence of converting enzyme activity in the rabbit basilar artery.
Zerrouk A; Auguet M; Delaflotte S; Chabrier PE
Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):466-73. PubMed ID: 8897450
[TBL] [Abstract][Full Text] [Related]
4. Vascular angiotensin conversion in humans.
Webb DJ; Collier JG
J Cardiovasc Pharmacol; 1986; 8 Suppl 10():S40-4. PubMed ID: 2438489
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin-converting enzyme two-week inhibition on renal angiotensin II receptors and renal vascular reactivity in SHR.
Haddad G; Garcia R
J Mol Cell Cardiol; 1997 Feb; 29(2):813-22. PubMed ID: 9140837
[TBL] [Abstract][Full Text] [Related]
6. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries.
Richard V; Hurel-Merle S; Scalbert E; Ferry G; Lallemand F; Bessou JP; Thuillez C
Circulation; 2001 Aug; 104(7):750-2. PubMed ID: 11502696
[TBL] [Abstract][Full Text] [Related]
7. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.
Linz W; Schölkens BA; Kaiser J; Just M; Qi BY; Albus U; Petry P
Cardiovasc Drugs Ther; 1989 Dec; 3(6):873-82. PubMed ID: 2535056
[TBL] [Abstract][Full Text] [Related]
8. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
McDonald JE; Padmanabhan N; Petrie MC; Hillier C; Connell JM; McMurray JJ
Circulation; 2001 Oct; 104(15):1805-8. PubMed ID: 11591618
[TBL] [Abstract][Full Text] [Related]
9. Local inhibition of bradykinin degradation in ischemic hearts.
Linz W; Martorana PA; Schölkens BA
J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
[TBL] [Abstract][Full Text] [Related]
10. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade.
Tom B; de Vries R; Saxena PR; Danser AH
Hypertension; 2001 Jul; 38(1):95-9. PubMed ID: 11463767
[TBL] [Abstract][Full Text] [Related]
11. [3H]ramiprilat binding to the angiotensin-converting enzyme in rat renal brush-border membranes: the effect of chloride.
Grima M; Mosser J; Welsch C; Barthelmebs M; Imbs JL
Eur J Pharmacol; 1991 Mar; 206(3):203-9. PubMed ID: 1649762
[TBL] [Abstract][Full Text] [Related]
12. Vascular angiotensin-converting enzyme expression regulates local angiotensin II.
Müller DN; Bohlender J; Hilgers KF; Dragun D; Costerousse O; Ménard J; Luft FC
Hypertension; 1997 Jan; 29(1 Pt 1):98-104. PubMed ID: 9039087
[TBL] [Abstract][Full Text] [Related]
13. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
[TBL] [Abstract][Full Text] [Related]
14. Role of endothelium in angiotensin II formation by the rat aorta and mesenteric arterial bed.
Leite R; Esteväo R; Resende AC; Salgado MC
Braz J Med Biol Res; 1997 May; 30(5):649-56. PubMed ID: 9283634
[TBL] [Abstract][Full Text] [Related]
15. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
[TBL] [Abstract][Full Text] [Related]
16. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts.
Schunkert H; Jackson B; Tang SS; Schoen FJ; Smits JF; Apstein CS; Lorell BH
Circulation; 1993 Apr; 87(4):1328-39. PubMed ID: 8384939
[TBL] [Abstract][Full Text] [Related]
17. Differences between angiotensin-converting enzyme inhibition and angiotensin II-AT1 antagonism on angiotensin-mediated responses in human internal mammary arteries.
Voors AA; Oosterga M; Buikema H; Mariani M; Grandjean JG; van Gilst WH
J Cardiovasc Pharmacol; 2003 Feb; 41(2):178-84. PubMed ID: 12548077
[TBL] [Abstract][Full Text] [Related]
18. Comparison of angiotensin-converting enzyme inhibitors in the rat in perfused hindlimbs and in vivo.
Nelissen-Vrancken MH; Leenders PJ; Bost JG; Struijker-Boudier HA; Smits JF
Eur J Pharmacol; 1992 Jun; 217(1):49-55. PubMed ID: 1327817
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney.
Stegbauer J; Vonend O; Oberhauser V; Rump LC
J Hypertens; 2003 Jul; 21(7):1391-9. PubMed ID: 12817189
[TBL] [Abstract][Full Text] [Related]
20. Captopril decreases vascular reactivity independently of changes in converting enzyme activity and prostaglandin release in the rat isolated kidney.
Chiba S; Quilley CP; Quilley J; McGiff JC
Eur J Pharmacol; 1982 Sep; 83(3-4):243-52. PubMed ID: 6293842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
